Overview

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
Phase:
Phase 3
Details
Lead Sponsor:
Avid Radiopharmaceuticals